First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

Qiao Liu1, Zhen Zhou2, Xia Luo1, Lidan Yi1, Liubao Peng1, Xiaomin Wan1, Chongqing Tan1* and Xiaohui Zeng3*

1Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China, 2Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia, 3Department of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, China

Objective: Three immune checkpoint inhibitors (ICIs), pembrolizumab, atezolizumab and cemiplimab, have been successively approved as first-line treatments for advanced non-small-cell lung cancer (NSCLC) patients with programmed cell death ligand 1 (PD-L1) expression of at least 50%. This study was designed to compare the cost-effectiveness of these three novel therapies in this patient population.

Material and Methods: Using Markov model and network meta-analysis, we conducted separate cost-effectiveness analyses for cemiplimab, pembrolizumab and atezolizumab among advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. Health states included progression-free survival, progressive disease, end-stage disease, and death. Clinical efficacy and safety data were derived from phase III clinical trials and health state utilities and costs data were collected from published resources. Two scenario analyses were conducted to assess the impact of varying subsequent anticancer therapies on the cost-effectiveness of these 3 ICIs and cost-effectiveness of pembrolizumab combined with chemotherapy versus these 3 first-line ICI monotherapies.

Results: In base case analysis, cemiplimab compared with pembrolizumab was associated with a gain of 0.44 quality-adjusted life-years (QALYs) and an increased cost of $23,084, resulting in an incremental cost-effectiveness ratio (ICER) of $52,998/QALY; cemiplimab compared with atezolizumab was associated with a gain of 0.13 QALYs and a decreased cost of $104,642, resulting in its dominance of atezolizumab. The first scenario analysis yielded similar results as our base case analysis. The second scenario analysis founded the ICERs for pembrolizumab plus chemotherapy were $393,359/QALY, $190,994/QALY and $33,230/QALY, respectively, compared with cemiplimab, pembrolizumab and atezolizumab.

Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. Our scenario analysis results supported the cemiplimab plus chemotherapy
INTRODUCTION

Lung cancer is the most common malignancy and the leading cause of cancer mortality worldwide (William et al., 2009). Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancers, and up to 46% of NSCLC cases have advanced diseases at the time of diagnosis (Miller et al., 2020). Decision making on the standard first-line treatment for advanced NSCLC is personalized, based mainly on driver aberration types and programmed cell death ligand 1 (PD-L1) expression levels (Ettinger et al., 2021). Over the past few decades, treating NSCLC patients with traditional platinum-doublet chemotherapy has obtained unsatisfactory therapeutic effect, with a median overall survival (OS) of less than 1 year and a 5-year survival rate of nearly 18% (William et al., 2009). Accumulating evidence have reported that a higher expression of PD-L1 was associated with a poorer clinical prognosis and greater resistance to chemotherapy in NSCLC patients (Creeelan, 2014). Immune checkpoint inhibitors (ICIs), as a novel class of anticancer drugs, have therefore hold a great therapeutic potential on the management of advanced NSCLC patients, especially those with a high level of PD-L1 expression (Gridelli and Casaluce, 2018; Hanna et al., 2020).

Up to now, the United States Food and Drug Administration (FDA) has successively approved 3 ICI monotherapies for the first-line treatment of advanced NSCLC patients with at least 50% tumor cells expressing PD-L1 (US Food and Drug Administration, 2016; US Food and Drug Administration, 2021a; US Food and Drug Administration, 2021b). Pembrolizumab is the first approved ICI that has demonstrated significantly greater survival benefits and fewer adverse events (AEs) compared with platinum-based chemotherapy in the clinical trials of KEYNOTE-024 and KEYNOTE-042 (Reck et al., 2016; Mok et al., 2019). In May 2020, atezolizumab became the second approved ICI proven effective among PD-1 selected advanced NSCLC patients based on the IMpower110 trial (Herbst et al., 2020). More recently in February 2021, data from the EMPower-Lung 1 clinical trial, documented a significantly improved OS and progression-free survival (PFS) with cemiplimab in patients with advanced NSCLC with PD-L1 of at least 50%, when compared with chemotherapy (Sezer et al., 2021). Informed by the clinical evidence, cemiplimab was approved as a new first-line option for this patient population.

It was estimated that there were 116,700 patients in the United States (United States) developing advanced NSCLC in 2020 (American Cancer Society, 2021), and nearly 25–35% of them are expected to express PD-L1 in at least 50% of tumor cells (D’Incecco et al., 2015; Kerr et al., 2015). This means that about 40,800 patients are potentially eligible for ICI therapies. Given the huge population of beneficiaries and the expected negative financial consequences, comparing the cost-effectiveness of these ICIs among this patient population in the United States is necessary to determine their appropriateness for widespread use (Tsevat and Moriates, 2018). Several previous US-based studies have evaluated the cost-effectiveness of pembrolizumab or atezolizumab versus platinum-based chemotherapy in the first-line setting of advanced NSCLC patients with PD-L1 of at least 50% (Huang et al., 2017; Peng et al., 2021). However, the generalizability of their findings to real-world settings may be limited, in which the ICIs are typically used preferentially over traditional chemotherapy. The priority of these 3 first-line ICI monotherapies has yet to be determined.

To inform the resource allocation decision, we conducted this study to compare the cost-effectiveness of cemiplimab with pembrolizumab and atezolizumab as the first-line treatment for advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective.

MATERIALS AND METHODS

Overview

Through mathematical modeling using TreeAge Pro software (version 2021, https://www.treeage.com/) and network meta-analysis (NMA) implemented in R software (version 4.0.4, http://www.r-project.org), we conducted an indirect cost-effectiveness comparison of 3 first-line ICI monotherapies for advanced NSCLC patients with PD-L1 of at least 50% from the United States health care sector perspective. This study collected and studied existing data, including clinical efficacy and safe data from published Phase III clinical trials, health state utilities and costs data from previous literature and publicly available United States database. Therefore, it is exempt from ethic review. Our study follows the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guideline.

Patients and Treatment

Three potential competing first-line ICI monotherapies were assessed in the model: cemiplimab, pembrolizumab and atezolizumab. A hypothetical cohort of advanced NSCLC patients aged 18 years or older with PD-L1 expressed in at least 50% of tumor cells and without driver molecular alterations was created in our model. We did not incorporate a platinum-based chemotherapy arm into the model although it is a common comparator in clinical trials, because it is no longer recommended as a preferred first-line treatment in the latest National Comprehensive Cancer Network (NCCN) guidelines for this patient population (Ettinger et al., 2021). After progressed on first-line ICI monotherapies, the subsequent anticancer therapies were provided if there were
sustained survival benefits. Patients assigned to cemiplimab had the option to continue cemiplimab with the addition of 4 cycles of chemotherapy (Sezer et al., 2021); patients assigned to pembrolizumab and atezolizumab would be permitted to receive chemotherapy, immunotherapy, and targeted therapy (Reck et al., 2016; Mok et al., 2019; Herbst et al., 2020). The usage of subsequent anticancer drug was based on NCCN guidelines as well as the availability of clinical data (Reck et al., 2016; Mok et al., 2019; Herbst et al., 2020; Ettinger et al., 2021). Supplementary Table S1 provided detailed information on first-line and subsequent treatment regimens.

**Model Construction**

We constructed a Markov model consisting of four health states: PFS, progressive disease (PD), end-stage disease and death (Figure 1). All patients initially entered the PFS health state, then received first-line cemiplimab, pembrolizumab or atezolizumab monotherapy until disease progression or intolerable toxicity. Individuals who experienced disease progression during first-line treatment could move to the PD health state and receive subsequent anticancer therapies. Individuals who were not eligible for subsequent anticancer therapies finally entered into end-stage health state and proceeded to best supportive care (BSC) (Ettinger et al., 2021). To reflect the actual clinical practice, patients were assumed to receive palliative care before death.

We built the Markov model with a 3-week cycle length to project the health and economic outcomes associated with each treatment over a lifetime horizon. The main output of the model was the incremental cost-effectiveness ratio (ICER) between the compared treatment strategies, which was calculated as the cost for each additional quality-adjusted life-year (QALY) gained. Costs were reported in 2021 United States dollars and an annual discount of 3% was adopted for both cost and health outcomes. This analysis chose a willingness-to-pay (WTP) threshold of $100,000 per QALY as a cost-effectiveness measure of one regimen relative to another alternative regimen (Neumann et al., 2014).

**Survival and Health State Utilities**

For first-line cemiplimab, transition probabilities were calculated from the EMPOWER-Lung 1 trial. Briefly, the OS and PFS data were graphically extracted from the published Kaplan-Meier curves, then fitted and extrapolated by log-logistic survival distribution based on statistical measures of goodness-of-fit [Akaike information criterion (AIC) and Bayesian information criterion (BIC)] (Supplementary Table S2 and Figure 1). The final log-logistic theta (θ) and kappa (κ) parameters were computed by R software. The survival probability at a given time cycle t was calculated following this formula: $S(t) = \frac{1}{1 + \exp(\theta t^\kappa)}$. For first-line pembrolizumab and atezolizumab, the estimation of transition probabilities were based on the hazard ratios (HRs) of PFS and OS for the two alternative strategies relative to cemiplimab, which was used to adjust survival probability ($S_{alternative\ strategies}(t) = \frac{1}{1 + \exp(\theta t^\kappa)^{HRs}}$) (Wu et al., 2012). Given the absence of relevant clinical trials with head-to-head comparisons, the HRs were generated in a NMA implemented in the R software, with using data derived from published clinical trials that compared ICI monotherapy versus chemotherapy in the target population, including EMPOWER-Lung 1, KEYNOTE-024, KEYNOTE-042 and IMpower110 trials (Supplementary Table S3). All log-logistic parameters and HRs used in the model were presented in Table 1.

We also incorporated in the model the discontinuation of first-line ICI monotherapy owing to adverse events (AEs), with transition probabilities estimated from clinical trials (Reck et al., 2016; Mok et al., 2019; Herbst et al., 2020; Sezer et al., 2021). The following formula was applied to convert the probabilities of AEs-related treatment discontinuation during a clinical trial period into a 1-cylice probability of the events: $p = 1 - \exp(-rt)$, where p indicates the probability, r is the instantaneous rate and t is the time period (Supplementary Table S4) (Briggs and Claxton, 2006). Finally, the long-term observed survival data for advanced NSCLC patients from the Surveillance, Epidemiology, and End Results data from 2000 to 2018 were applied to estimate survival after patients entering end-stage disease health state, to ensure the OS of advanced NSCLC closely reflect the real-world performance (Supplementary Table S5) (National Cancer Institute Surveillance and End Results Program, 2021).

For all model groups, the health utilities were derived from the European Quality of Life 5 Dimensions-3 Level (EQ-5D-3L) data reported in the KEYNOTE-024 trial (Brahmer et al., 2017). The time-to-death approach was applied to reflect the decline in quality-of-life in patients with advanced NSCLC as they approach death (Hatswell et al., 2014). In addition, the utility decrements for common grade III/IV AEs as a result of first-line treatment were considered in our model (Supplementary Table S6) (Nafees et al., 2017).
Cost Estimates

We collected direct medical costs from the United States health care sector perspective, including first- and second-line drug acquisition and administration costs, AEs management costs and general treatment costs of advanced NSCLC (such as routine follow-up costs, BSC costs, and death-associated costs). Cost inputs used in the model were outlined in Table 1.

Drug prices were collected from the Centers for Medicare and Medicaid Services (CMS) 2021 Average Sales Price drug...
Pricing Files (Centers for Medicare and, 2021a). In calculating the drug dosage, we used a body weight of 70.32 kg, a body surface area of 1.79 m² and a creatinine clearance rate of 70 ml/min for model base case patients (Criss et al., 2019; Zhang et al., 2020). Drug administration costs were searched from the CMS Physician Fee Schedule Look-up Tool updated in January 2021 (Centers for Medicare and, 2021b). For drugs with infusion time requirements, we modeled the duration of ICI monotherapy and chemotherapy as 1 h per cycle and 3 h per cycle, respectively (Zhang et al., 2020).

Costs for managing grade III/IV AEs with an incidence of at least 1% were considered in the model (Reck et al., 2016; Mok et al., 2019; Herbst et al., 2020; Sezer et al., 2021). To calculate the AEs costs for each first-line treatments, we multiplied the incidence of each AE observed in the corresponding clinical trials by its management cost, and then summarize these costs to generate the cumulative cost. The AEs management costs were derived from the Healthcare Cost and Utilization Project (HCUP) using Clinical Classification Software Refined (CCSR) diagnosis (Supplementary Table S6) (Agency for Healthcare Res, 2021). We assumed that patients would receive a monthly physician visit and a three-monthly imaging examination during the routine follow-up. BSC cost and death-associated costs were sourced from published literature (Criss et al., 2019).

### Sensitivity Analysis

To assess the uncertainty in the model, both deterministic sensitivity analyses (DSA) and probabilistic sensitivity analyses (PSA) were employed. During DSA, model parameters varied individually, while other parameters were fixed to determine their roles in the ICERs. We defined the reported 95% (confidence Intervals) CIs as the test ranges for HRs and Utility values, whereas the ±50% of the baseline values as the test ranges for other parameters. During PSA, each model parameter followed an appropriate statistical distribution, and 10,000 Monte Carlo simulations were performed using random sampling of model parameters from the distributions each time. All ranges and distributions of model parameters were detailed in Table 1.

We also conducted two scenario analyses. First, we assumed that the same subsequent anticancer therapy regimen (cemiplimab plus 4 cycles chemotherapy) was used in these three first-line ICI monotherapy groups, using survival data from the EMPower-Lung 1 trial. This scenario allowed a brief comparative analysis of different subsequent anticancer therapies from the perspectives of cost and effectiveness. In the second scenario analysis, we incorporated a pembrolizumab plus chemotherapy group in our model and used the results of a MNA focusing on the efficacy of first-line pembrolizumab versus pembrolizumab plus chemotherapy in the treatment of advanced NSCLC (Kim et al., 2019). This scenario allowed us to conservatively predict the cost-effectiveness of ICI combined with chemotherapy versus ICI monotherapy in the absence of head-to-head clinical data.

### RESULTS

#### Incremental Cost-Effectiveness Ratios

In our base case analysis, treating patients with first-line cemiplimab monotherapy compared with first-line pembrolizumab and atezolizumab monotherapy were associated with improved survivals of 0.44 QALYs and 0.13 QALYs, respectively. In addition, the healthcare cost caused by cemiplimab was greater than pembrolizumab ($231,338 vs. $217,456) but substantially lower than atezolizumab ($231,338 vs $332,126) (Table 2). The results showed that first-line cemiplimab was a cost-effective option compared with first-line pembrolizumab (ICER = $23,083/QALY), and a dominant alternative against first-line atezolizumab when the WTP threshold set as $100,000/QALY.

In the first scenario analysis, the use of cemiplimab plus chemotherapy, as the only subsequent anticancer therapy, resulted in incremental effectiveness of 0.19 QALYs (2.85 vs. 2.65 QALYs) and 0.05 QALYs (3.02 vs. 2.97 QALYs) in the first-line pembrolizumab and atezolizumab groups, compared with our base case results. In the second scenario analysis, we incorporated a pembrolizumab plus chemotherapy group in our model and found that treating patients with pembrolizumab plus chemotherapy in the first-line setting was associated with a mean cost of $350,281 and a mean survival of 3.40 QALYs. The model results showed that, when compared with cemiplimab, pembrolizumab and atezolizumab, the ICERS for pembrolizumab plus chemotherapy were $393,359/QALY, $190,994/QALY and $33,230/QALY, respectively (Table 2).

#### Sensitivity Analysis

The DSA of the base case analysis revealed that, the fluctuation of any tested model parameter, except for the price per mg of cemiplimab and pembrolizumab, was unable to change the cost-effectiveness advantage of first-line cemiplimab over first-line pembrolizumab. More specifically, either increasing the price per mg of cemiplimab from $27.58 to more than $30.40 or decreasing the price per mg of pembrolizumab from $ 51.35 to less than $ 43.26, would bring the ICERS above the WTP threshold of $100,000/QALY. Other model parameters, such as the HRs of OS and PFS for the fist-line pembrolizumab and atezolizumab strategy relative to the fist-line cemiplimab, and the price per mg of second-line ramucirumab had a moderate influence on the ICER. The top 10 parameters by magnitude of effect on the ICER were presented in Figure 2.

In the first scenario analysis, the most influential parameters with the ability to reverse our model results regarding the cost-effectiveness of first-line cemiplimab versus pembrolizumab remained the price per mg of cemiplimab and pembrolizumab. In addition, the price of subsequent anticancer therapy drugs, such as the price per mg of ramucirumab and nivolumab, which had considerable impacts on our base case analysis results, was no longer ranked in the top 10 parameters with the greatest associations with the ICER between first-line cemiplimab and pembrolizumab (Supplementary Figure S3). In the second scenario
In performing PSA for the base case analysis, first-line cemiplimab was cost-effective in 71.1% of iterations and dominant in 11.2% of iterations compared with first-line pembrolizumab (Figure 3). In the first scenario analysis, first-line cemiplimab was cost-effective in 79.4% of iterations and dominant in 18.2% of iterations compared with first-line pembrolizumab. In the second scenario analysis, compared with first-line cemiplimab, first-line pembrolizumab plus chemotherapy was not cost-effective in 72.2% of iterations and was dominated in 32.1% of iterations.

**TABLE 2 | Summary of simulation results**

| Analysis                      | Cost, $ | QALYs | Incremental ICER, $/QALY |
|-------------------------------|---------|-------|--------------------------|
|                               |         |       | Cost, $ | QALYs |                               |
| **Base case analysis**        |         |       |                       |       |
| First-line cemiplimab         | 231,338 | 3.10  | NA       | NA       | Dominated (-104,642, 0.13)    |
| vs. First-line atezolizumab   | 335,980 | 2.97  | 104,642  | 0.13     | (cost-effective)              |
| vs. First-line pembrolizumab  | 208,254 | 2.65  | 23,084   | 0.44     | 52,998 (cost-effective)       |
| **First scenario analysis**  |         |       |                       |       |
| First-line cemiplimab         | 231,338 | 3.10  | NA       | NA       | Dominated (-70,937, 0.08)    |
| vs. First-line atezolizumab   | 302,274 | 3.02  | 70,937   | 0.08     | (cost-effective)              |
| vs. First-line pembrolizumab  | 219,623 | 2.85  | 11,714   | 0.25     | 47,124 (cost-effective)       |
| **Second scenario analysis** |         |       |                       |       |
| First-line Pembrolizumab plus |         |       |                       |       |
| Chemotherapy                  | 350,281 | 3.40  | NA       | NA       | Dominated (14,301, 0.43)     |
| vs. First-line atezolizumab   | 335,980 | 2.97  | 14,301   | 0.43     | 33,230 (cost-effective)       |
| vs. First-line pembrolizumab  | 208,254 | 2.65  | 142,027  | 0.75     | 190,994 (not cost-effective)  |
| vs. First-line cemiplimab     | 231,338 | 3.10  | 118,943  | 0.30     | 393,359 (not cost-effective)  |

QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.

**FIGURE 2 | Deterministic sensitivity analysis for the base case analysis.** ICER, incremental cost-effectiveness ratios; QALY, quality-adjusted life-years; OS, overall survival; PFS, progression-free survival; HR, hazard ratios; AEs, adverse events; BSC, best supportive care.
DISCUSSION

In this cost-effectiveness analysis, our base case results suggested that cemiplimab was a cost-effective treatment strategy in comparison to pembrolizumab with an ICER of 52,998/QALY, and a dominant alternative against atezolizumab. In our first scenario analysis examining the impact of subsequent anticancer therapy regimen on the model outputs, we reached the same conclusion as the base case analysis. In the second scenario analysis evaluating the cost-effectiveness for different ICI treatment paradigms, model results suggested that first-line pembrolizumab plus chemotherapy was inferior to cemiplimab monotherapy and pembrolizumab monotherapy but was superior to atezolizumab monotherapy. To our best knowledge, this is the first cost-effectiveness analysis focusing on the newly approved ICI cemiplimab for advanced NSCLC with PD-L1 of at least 50% from the United States perspective and the first to compare these 3 ICI monotherapies (pembrolizumab, atezolizumab and cemiplimab) approved as the preferred upfront therapy. Given that more than one-tenth of the newly diagnosed lung cancer cases in the world occurred in the United States (Bray et al., 2018; Miller et al., 2020), our findings will have a significant impact on reducing both national and global lung cancer burden at a population-based level by providing the useful evidence on the comparative cost-effectiveness of three novel immunotherapies. The United States is a representative developed country which implies that our study findings may also be applicable to countries with similar health sectors.

Sensitivity analyses revealed that the price of ICIs plays a crucial role in determining the cost-effectiveness of one regimen relative to another alternative regimen. Our results were in line with the findings of several previous studies (Criss et al., 2019; Wan et al., 2019; Watson et al., 2020), stimulating debates on pricing scheme for cancer drugs. The United States policy researchers have paid great efforts on determining drug prices in terms of drug’s benefits, such as indication-specific pricing, value-based pricing and the "Netfix Model" (Bach, 2014; Bach and Pearson, 2015; Trusheim et al., 2018). However, due to the relatively unrestrained pricing power given to drug manufacturers by the United States law, private insurers are unable to obtain reasonable drug prices (Prasad and Mailankody, 2016). As a result, drug prices in the United States are generally higher than those in other major industrialized countries (Comparative price report, 2013), and are usually independent of drug novelty (Mailankody and Prasad, 2015). As cancer drug prices are already alarmingly high and rising faster than the prices of drugs used in other health care sectors in the United States (Bach, 2009; Mailankody and Prasad, 2014), there is an urgent need to update relevant policies to ensure the cancer drug prices commensurate with their clinical benefits. These price policy recommendations may include but not limited to value-based pricing as informed by this study (Bach and Pearson, 2015), price negotiation between governments and the pharmaceuticals (Tang et al., 2020), and government-subsidized medication schemes (Duckett, 2004). Apart from the drug price, HR is another equally important parameter that considerably influences the robustness of our model. It is worth noting that HR is an important factor in determining QALY gain, and it is relatively difficult to change it through policy intervention. Therefore, price adjustment would be the most

FIGURE 3 | Cost-effectiveness acceptability curves for the base case analysis. The red curve signifies the probability of first-line cemiplimab being cost-effective against first-line pembrolizumab under different WTP thresholds. QALY, quality-adjusted life-year.
realistic means that can be taken to make an ICI-based therapy cost-effective.

In the first scenario analysis, although our attempts to unify the subsequent anticancer therapy in these three first-line ICI monotherapy groups did not significantly change our results, the increases in QALYs in the first-line pembrolizumab and atezolizumab groups compared with our base case results may support a case for expanding the cemiplimab plus chemotherapy indication to second-line settings for advanced NSCLC patients with PD-L1 of at least 50%. The second scenario analysis results showed that first-line pembrolizumab plus chemotherapy was associated with incremental effectiveness compared with these 3 first-line ICI monotherapy, due mainly to a lower rate of early treatment failures with combination therapy than the ICI monotherapy (Di Federico et al., 2021).

This analysis has several notable strengths. First, we exhausted all available clinical trial data and authoritative MNA results to compare the lifetime healthcare cost and clinical outcomes of all first-line therapy preferentially approved by FDA, including three ICI monotherapies and one ICI combination therapy, which may add important cost-effectiveness evidence to inform the preferred treatment options for advanced NSCLC patients with PD-L1 of at least 50%. Second, the long-term survival estimates for model patients were based on the Surveillance, Epidemiology, and End Results data from 2000 to 2018. By using the real-world data, the underlying uncertainty caused by directly extrapolating survival from the fitted survival distributions was avoided (Wan et al., 2019). Third, we considered first-line treatment discontinuation due to AEs, as well as the impact of grade III/IV AEs on medical cost and utility in our model to refine the simulation of our model.

This study also has several limitations. First, due to the lack of clinical data comparing these 3 ICI monotherapies head-to-head, or ICI combined chemotherapy with ICI monotherapy with in one trial, the results of NMA were used for the analysis of an indirect cost-effectiveness comparison. Although the results from sensitivity analyses suggested that changing HRs did not alter the results of our base case analysis and the first scenario analysis, it may reverse the results of the second scenario analysis. Nonetheless, the second scenario analysis should be viewed as a tentative evaluation in the absence of head-to-head trials, and the model could be validated when more mature clinical data are available. Second, to simplify the model, we have made some assumptions regarding subsequent anticancer drugs, because the specific drugs information in corresponding clinical trials is not available. This assumption may bias the model against cost estimates. However, our findings were found to be robust over a wide range of variations in the price of subsequent anticancer drugs. Third, we modeled lower proportions of patients receiving second-line ICI in the first-line pembrolizumab and atezolizumab groups based on subsequent anticancer therapy data derived from clinical trials (Reck et al., 2016; Mok et al., 2019; Herbst et al., 2020; Sezer et al., 2021). There is an uncertainty regarding whether patients whose cancer progressed on first-line ICI monotherapy would continue to benefit from further ICI treatment. However, we explored this in our first scenario analysis by modeling the subsequent anticancer therapy of these 3 first-line ICI monotherapy as cemiplimab plus chemotherapy.

In conclusion, in this economic evaluation comparing the 3 approved first-line therapies for advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective treatment strategy compared to pembrolizumab, and a dominant alternative against atezolizumab. The results of our scenario analysis support the use of cemiplimab plus chemotherapy as a potential second-line therapy for this patient population and suggested that pembrolizumab plus chemotherapy was associated with extended QALY but an overwhelming cost. Our findings highlight the need for the United States policymakers to develop pricing schemes that can make drug prices commensurate with their values.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

XZ and CT contributed to the conception, design of the primarily model and interpreted the results. QL and ZZ developed the economic model, performed the analyses and drafted the manuscript. XL and LY collected and reviewed data. QL, LP and XW provided clinical input, validated the model assumptions. All authors read and approved the final manuscript.

FUNDING

This work was supported by the Hunan Provincial Natural Science Foundation (grant numbers 2019JJ50864); Hunan Provincial Natural Science Foundation (grant numbers 2021JJ80080).

ACKNOWLEDGMENTS

I certify that no individuals other than the listed co-authors contributed to this publication.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.788569/full#supplementary-material
approves-atezolizumab-first-line-treatment-metastatic-nscle-high-pd-l1-expression. (Accessed March 5, 2021)
Us Food and Drug Administration (2021b). FDA Approves Cemiplimab-Rwlc for Non-small Cell Lung Cancer with High PD-L1 Expression. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-non-small-cell-lung-cancer-high-pd-l1-expression (Accessed May 2, 2021)
Us Food and Drug Administration (2016). Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/pembrolizumab-keytruda-checkpoint-inhibitor. (Accessed June 26, 2021)
Wan, X., Zhang, Y., Tan, C., Zeng, X., and Peng, L. (2019). First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis. JAMA Oncol. 5 (4), 491–496. doi:10.1001/jamaoncol.2018.7086
Watson, T. R., Gao, X., Reynolds, K. L., and Kong, C. Y. (2020). Cost-effectiveness of Pembrolizumab Plus Axitinib vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US. JAMA Netw. Open 3 (10), e2016144. doi:10.1001/jamenetworkopen.2020.16144
William, W. N., Jr., Lin, H. Y., Lee, J. J., Lippman, S. M., Roth, J. A., and Kim, E. S. (2009). Revisiting Stage IIIB and IV Non-small Cell Lung Cancer: Analysis of the Surveillance, Epidemiology, and End Results Data. Chest 136 (3), 701–709. doi:10.1378/chest.08-2968
Wu, B., Dong, B., Xu, Y., Zhang, Q., Shen, J., Chen, H., et al. (2012). Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: a Cost-Effectiveness Analysis in a Health Resource-Limited Setting. PloS one 7 (3), e32530. doi:10.1371/journal.pone.0032530
Zhang, L., Hang, Y., Liu, M., Li, N., and Cai, H. (2020). First-Line Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis. Front. Oncol. 10, 602185. doi:10.3389/fonc.2020.602185

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Liu, Zhou, Luo, Yi, Peng, Wan, Tan and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.